Knowledge Centre

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Categories

Information

Knowledge Centre

IMM-124E Improves metabolic endotoxemia and markers of liver injury in nonalcoholic steatohepatitis

Travelan travellers' diarrhoea - Otto Study

The gut microbiome and NASH

Gut microbiota, intestinal permeability, obesity-induced inflammation and liver injury

Passive immunity against human pathogens using bovine antibodies

Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin and medical consequences

Platform Science

Product Science

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information